semaglutide and cholecystitis GLP-1 receptor agonists gallbladder disease risk: insights into molecular mechanisms and clinical implications Ozempic After Gallbladder Removal: Safety

nine participants (4.8%) had serious AEs

I found myself wondering how long it would take before I noticed real results

The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities

Known generically as semaglutide, Ozempic works by mimicking a hormone that regulates appetite and food intake, leading many patients to experience notable weight reduction

How GLP-1 and GIP pathways work, why dual-action tirzepatide (Mounjaro) differs from GLP-1-only medicines, and what trial averages mean for UK patients.

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research